Heart fatty acid binding protein and Aβ-associated Alzheimer’s neurodegeneration

go back to reference Shepardson NE, Shankar GM, Selkoe DJ: Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch Neurol. 2011, 68: 1239-1244. 10.1001/archneurol.2011.203.PubMedCentralCrossRefPubMed Shepardson NE, Shankar GM, Selkoe DJ: Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch Neurol. 2011, 68: 1239-1244. 10.1001/archneurol.2011.203.PubMedCentralCrossRefPubMed

go back to reference Shepardson NE, Shankar GM, Selkoe DJ: Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch Neurol. 2011, 68: 1385-1392. 10.1001/archneurol.2011.242.PubMedCentralCrossRefPubMed Shepardson NE, Shankar GM, Selkoe DJ: Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch Neurol. 2011, 68: 1385-1392. 10.1001/archneurol.2011.242.PubMedCentralCrossRefPubMed

go back to reference Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, Pocklington A, Abraham R, Hollingworth P, Sims R, Gerrish A, Pahwa JS, Jones N, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schürmann B, Heun R, Kölsch H, van den Bussche H, Heuser I, Peters O, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, Wichmann HE, Rüther E, Carrasquillo MM, Pankratz VS, Younkin SG, Hardy J, O’Donovan MC, Owen MJ, Williams J: Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer’s disease. PLoS One. 2010, 5: e13950-10.1371/journal.pone.0013950.PubMedCentralCrossRefPubMed Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, Pocklington A, Abraham R, Hollingworth P, Sims R, Gerrish A, Pahwa JS, Jones N, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schürmann B, Heun R, Kölsch H, van den Bussche H, Heuser I, Peters O, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, Wichmann HE, Rüther E, Carrasquillo MM, Pankratz VS, Younkin SG, Hardy J, O’Donovan MC, Owen MJ, Williams J: Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer’s disease. PLoS One. 2010, 5: e13950-10.1371/journal.pone.0013950.PubMedCentralCrossRefPubMed

go back to reference Jones L, Harold D, Williams J: Genetic evidence for the involvement of lipid metabolism in Alzheimer’s disease. Biochim Biophys Acta. 1801, 2010: 754-761. Jones L, Harold D, Williams J: Genetic evidence for the involvement of lipid metabolism in Alzheimer’s disease. Biochim Biophys Acta. 1801, 2010: 754-761.

go back to reference Di Paolo G, Kim TW: Linking lipids to Alzheimer’s disease: cholesterol and beyond. Nat Rev Neurosci. 2011, 12: 284-296. 10.1038/nrn3012.PubMedCentralCrossRefPubMed Di Paolo G, Kim TW: Linking lipids to Alzheimer’s disease: cholesterol and beyond. Nat Rev Neurosci. 2011, 12: 284-296. 10.1038/nrn3012.PubMedCentralCrossRefPubMed

go back to reference Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, Paul SM, Holtzman DM: Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest. 2008, 118: 671-682.PubMedCentralPubMed Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, Paul SM, Holtzman DM: Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest. 2008, 118: 671-682.PubMedCentralPubMed

go back to reference Castellano JM, Deane R, Gottesdiener AJ, Verghese PB, Stewart FR, West T, Paoletti AC, Kasper TR, DeMattos RB, Zlokovic BV, Holtzman DM: Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proc Natl Acad Sci USA. 2012, 109: 15502-15507. 10.1073/pnas.1206446109.PubMedCentralCrossRefPubMed Castellano JM, Deane R, Gottesdiener AJ, Verghese PB, Stewart FR, West T, Paoletti AC, Kasper TR, DeMattos RB, Zlokovic BV, Holtzman DM: Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proc Natl Acad Sci USA. 2012, 109: 15502-15507. 10.1073/pnas.1206446109.PubMedCentralCrossRefPubMed

go back to reference Reitz C, Luchsinger J, Tang MX, Manly J, Mayeux R: Impact of plasma lipids and time on memory performance in healthy elderly without dementia. Neurology. 2005, 64: 1378-1383. 10.1212/01.WNL.0000158274.31318.3C.PubMedCentralCrossRefPubMed Reitz C, Luchsinger J, Tang MX, Manly J, Mayeux R: Impact of plasma lipids and time on memory performance in healthy elderly without dementia. Neurology. 2005, 64: 1378-1383. 10.1212/01.WNL.0000158274.31318.3C.PubMedCentralCrossRefPubMed

go back to reference Reitz C, Tang MX, Manly J, Schupf N, Mayeux R, Luchsinger JA: Plasma lipid levels in the elderly are not associated with the risk of mild cognitive impairment. Dement Geriatr Cogn Disord. 2008, 25: 232-237. 10.1159/000115847.PubMedCentralCrossRefPubMed Reitz C, Tang MX, Manly J, Schupf N, Mayeux R, Luchsinger JA: Plasma lipid levels in the elderly are not associated with the risk of mild cognitive impairment. Dement Geriatr Cogn Disord. 2008, 25: 232-237. 10.1159/000115847.PubMedCentralCrossRefPubMed

go back to reference Cheon MS, Kim SH, Fountoulakis M, Lubec G: Heart type fatty acid binding protein (H-FABP) is decreased in brains of patients with Down syndrome and Alzheimer’s disease. J Neural Transm Suppl. 2003, 67: 225-34. 10.1007/978-3-7091-6721-2_20.CrossRefPubMed Cheon MS, Kim SH, Fountoulakis M, Lubec G: Heart type fatty acid binding protein (H-FABP) is decreased in brains of patients with Down syndrome and Alzheimer’s disease. J Neural Transm Suppl. 2003, 67: 225-34. 10.1007/978-3-7091-6721-2_20.CrossRefPubMed

go back to reference Freeman SH, Kandel R, Cruz L, Rozkalne A, Newell K, Frosch MP, Hedley-Whyte ET, Locascio JJ, Lipsitz LA, Hyman BT: Preservation of neuronal number despite age-related cortical brain atrophy in elderly subjects without Alzheimer disease. J Neuropathol Exp Neurol. 2008, 67: 1205-1212. 10.1097/NEN.0b013e31818fc72f.PubMedCentralCrossRefPubMed Freeman SH, Kandel R, Cruz L, Rozkalne A, Newell K, Frosch MP, Hedley-Whyte ET, Locascio JJ, Lipsitz LA, Hyman BT: Preservation of neuronal number despite age-related cortical brain atrophy in elderly subjects without Alzheimer disease. J Neuropathol Exp Neurol. 2008, 67: 1205-1212. 10.1097/NEN.0b013e31818fc72f.PubMedCentralCrossRefPubMed

go back to reference Bobinski M, de Leon MJ, Wegiel J, Desanti S, Convit A, Saint Louis LA, Rusinek H, Wisniewski HM: The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer’s disease. Neuroscience. 2000, 95: 721-725.CrossRefPubMed Bobinski M, de Leon MJ, Wegiel J, Desanti S, Convit A, Saint Louis LA, Rusinek H, Wisniewski HM: The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer’s disease. Neuroscience. 2000, 95: 721-725.CrossRefPubMed

go back to reference Blennow K, Hampel H, Weiner M, Zetterberg H: Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010, 6: 131-144. 10.1038/nrneurol.2010.4.CrossRefPubMed Blennow K, Hampel H, Weiner M, Zetterberg H: Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010, 6: 131-144. 10.1038/nrneurol.2010.4.CrossRefPubMed

go back to reference Fagan AM, Holtzman DM: Cerebrospinal fluid biomarkers of Alzheimer’s disease. Biomark Med. 2010, 4: 51-63. 10.2217/bmm.09.83.PubMedCentralCrossRefPubMed Fagan AM, Holtzman DM: Cerebrospinal fluid biomarkers of Alzheimer’s disease. Biomark Med. 2010, 4: 51-63. 10.2217/bmm.09.83.PubMedCentralCrossRefPubMed

go back to reference Moullé VS, Cansell C, Luquet S, Cruciani-Guglielmacci C: The multiple roles of fatty acid handling proteins in brain. Front Physiol. 2012, 3: 385-PubMedCentralCrossRefPubMed Moullé VS, Cansell C, Luquet S, Cruciani-Guglielmacci C: The multiple roles of fatty acid handling proteins in brain. Front Physiol. 2012, 3: 385-PubMedCentralCrossRefPubMed

go back to reference Chiasserini D, Parnetti L, Andreasson U, Zetterberg H, Giannandrea D, Calabresi P, Blennow K: CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer’s disease. J Alzheimers Dis. 2010, 22: 1281-1288.PubMed Chiasserini D, Parnetti L, Andreasson U, Zetterberg H, Giannandrea D, Calabresi P, Blennow K: CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer’s disease. J Alzheimers Dis. 2010, 22: 1281-1288.PubMed

go back to reference Rosén C, Mattsson N, Johansson PM, Andreasson U, Wallin A, Hansson O, Johansson JO, Lamont J, Svensson J, Blennow K, Zetterberg H: Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases. Front Aging Neurosci. 2011, 3: 1-PubMedCentralCrossRefPubMed Rosén C, Mattsson N, Johansson PM, Andreasson U, Wallin A, Hansson O, Johansson JO, Lamont J, Svensson J, Blennow K, Zetterberg H: Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases. Front Aging Neurosci. 2011, 3: 1-PubMedCentralCrossRefPubMed

go back to reference Olsson B, Hertze J, Ohlsson M, Nägga K, Höglund K, Basun H, Annas P, Lannfelt L, Andreasen N, Minthon L, Zetterberg H, Blennow K, Hansson O: Cerebrospinal Fluid Levels of Heart Fatty Acid Binding Protein are Elevated Prodromally in Alzheimer’s Disease and Vascular Dementia. J Alzheimers Dis. 2012, Dec 19 Olsson B, Hertze J, Ohlsson M, Nägga K, Höglund K, Basun H, Annas P, Lannfelt L, Andreasen N, Minthon L, Zetterberg H, Blennow K, Hansson O: Cerebrospinal Fluid Levels of Heart Fatty Acid Binding Protein are Elevated Prodromally in Alzheimer’s Disease and Vascular Dementia. J Alzheimers Dis. 2012, Dec 19

go back to reference Olsson B, Hertze J, Ohlsson M, Nägga K, Höglund K, Basun H, Annas P, Lannfelt L, Andreasen N, Minthon L, Zetterberg H, Blennow K, Hansson O: Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia. J Alzheimers Dis. 2013, 34 (3): 673-9.PubMed Olsson B, Hertze J, Ohlsson M, Nägga K, Höglund K, Basun H, Annas P, Lannfelt L, Andreasen N, Minthon L, Zetterberg H, Blennow K, Hansson O: Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia. J Alzheimers Dis. 2013, 34 (3): 673-9.PubMed

go back to reference Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ: Alzheimer’s Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 2009, 65: 403-13. 10.1002/ana.21610.PubMedCentralCrossRefPubMed Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ: Alzheimer’s Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 2009, 65: 403-13. 10.1002/ana.21610.PubMedCentralCrossRefPubMed

go back to reference Schon EA, Area-Gomez E: Mitochondria-associated ER membranes in Alzheimer disease. Mol Cell Neurosci. 2013, 55: 26-36.CrossRefPubMed Schon EA, Area-Gomez E: Mitochondria-associated ER membranes in Alzheimer disease. Mol Cell Neurosci. 2013, 55: 26-36.CrossRefPubMed

go back to reference Vetrivel KS, Thinakaran G: Membrane rafts in Alzheimer’s disease beta-amyloid production. Biochim Biophys Acta. 1801, 2010: 860-7. Vetrivel KS, Thinakaran G: Membrane rafts in Alzheimer’s disease beta-amyloid production. Biochim Biophys Acta. 1801, 2010: 860-7.

go back to reference Sanchez-Mejia RO, Mucke L: Phospholipase A2 and arachidonic acid in Alzheimer’s disease. Biochim Biophys Acta. 1801, 2010: 784-90. Sanchez-Mejia RO, Mucke L: Phospholipase A2 and arachidonic acid in Alzheimer’s disease. Biochim Biophys Acta. 1801, 2010: 784-90.

go back to reference Steinacker P, Mollenhauer B, Bibl M, Cepek L, Esselmann H, Brechlin P, Lewczuk P, Poser S, Kretzschmar HA, Wiltfang J, Trenkwalder C, Otto M: Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett. 2004, 370: 36-9. 10.1016/j.neulet.2004.07.061.CrossRefPubMed Steinacker P, Mollenhauer B, Bibl M, Cepek L, Esselmann H, Brechlin P, Lewczuk P, Poser S, Kretzschmar HA, Wiltfang J, Trenkwalder C, Otto M: Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett. 2004, 370: 36-9. 10.1016/j.neulet.2004.07.061.CrossRefPubMed

go back to reference Mollenhauer B, Steinacker P, Bahn E, Bibl M, Brechlin P, Schlossmacher MG, Locascio JJ, Wiltfang J, Kretzschmar HA, Poser S, Trenkwalder C, Otto M: Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies. Neurodegener Dis. 2007, 4: 366-75. 10.1159/000105157.CrossRefPubMed Mollenhauer B, Steinacker P, Bahn E, Bibl M, Brechlin P, Schlossmacher MG, Locascio JJ, Wiltfang J, Kretzschmar HA, Poser S, Trenkwalder C, Otto M: Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies. Neurodegener Dis. 2007, 4: 366-75. 10.1159/000105157.CrossRefPubMed

go back to reference Wada-Isoe K, Imamura K, Kitamaya M, Kowa H, Nakashima K: Serum heart-fatty acid binding protein levels in patients with Lewy body disease. J Neurol Sci. 2008, 266: 20-24. 10.1016/j.jns.2007.08.018.CrossRefPubMed Wada-Isoe K, Imamura K, Kitamaya M, Kowa H, Nakashima K: Serum heart-fatty acid binding protein levels in patients with Lewy body disease. J Neurol Sci. 2008, 266: 20-24. 10.1016/j.jns.2007.08.018.CrossRefPubMed

go back to reference Ohrfelt A, Andreasson U, Simon A, Zetterberg H, Edman A, Potter W, Holder D, Devanarayan V, Seeburger J, Smith AD, Blennow K, Wallin A: Screening for new biomarkers for subcortical vascular dementia and Alzheimer’s disease. Dement Geriatr Cogn Dis Extra. 2011, 1: 31-42. 10.1159/000323417.PubMedCentralCrossRefPubMed Ohrfelt A, Andreasson U, Simon A, Zetterberg H, Edman A, Potter W, Holder D, Devanarayan V, Seeburger J, Smith AD, Blennow K, Wallin A: Screening for new biomarkers for subcortical vascular dementia and Alzheimer’s disease. Dement Geriatr Cogn Dis Extra. 2011, 1: 31-42. 10.1159/000323417.PubMedCentralCrossRefPubMed

go back to reference Mauch DH, Nägler K, Schumacher S, Göritz C, Müller EC, Otto A, Pfrieger FW: CNS synaptogenesis promoted by glia-derived cholesterol. Science. 2001, 294: 1354-7. 10.1126/science.294.5545.1354.CrossRefPubMed Mauch DH, Nägler K, Schumacher S, Göritz C, Müller EC, Otto A, Pfrieger FW: CNS synaptogenesis promoted by glia-derived cholesterol. Science. 2001, 294: 1354-7. 10.1126/science.294.5545.1354.CrossRefPubMed

go back to reference Fortin DL, Troyer MD, Nakamura K, Kubo S, Anthony MD, Edwards RH: Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci. 2004, 24: 6715-23. 10.1523/JNEUROSCI.1594-04.2004.CrossRefPubMed Fortin DL, Troyer MD, Nakamura K, Kubo S, Anthony MD, Edwards RH: Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci. 2004, 24: 6715-23. 10.1523/JNEUROSCI.1594-04.2004.CrossRefPubMed

go back to reference Büttner S, Delay C, Franssens V, Bammens T, Ruli D, Zaunschirm S, de Oliveira RM, Outeiro TF, Madeo F, Buée L, Galas MC, Winderickx J: Synphilin-1 enhances α-synuclein aggregation in yeast and contributes to cellular stress and cell death in a Sir2-dependent manner. PLoS One. 2010, 5: e13700-10.1371/journal.pone.0013700.PubMedCentralCrossRefPubMed Büttner S, Delay C, Franssens V, Bammens T, Ruli D, Zaunschirm S, de Oliveira RM, Outeiro TF, Madeo F, Buée L, Galas MC, Winderickx J: Synphilin-1 enhances α-synuclein aggregation in yeast and contributes to cellular stress and cell death in a Sir2-dependent manner. PLoS One. 2010, 5: e13700-10.1371/journal.pone.0013700.PubMedCentralCrossRefPubMed

go back to reference Taylor DR, Hooper NM: The prion protein and lipid rafts. Mol Membr Biol. 2006, 23: 89-99. 10.1080/09687860500449994.CrossRefPubMed Taylor DR, Hooper NM: The prion protein and lipid rafts. Mol Membr Biol. 2006, 23: 89-99. 10.1080/09687860500449994.CrossRefPubMed

go back to reference Westaway D, Jhamandas JH: The P’s and Q’s of cellular PrP-Aβ interactions. Prion. 2012, 6: 359-63. 10.4161/pri.20675.PubMedCentralCrossRefPubMed Westaway D, Jhamandas JH: The P’s and Q’s of cellular PrP-Aβ interactions. Prion. 2012, 6: 359-63. 10.4161/pri.20675.PubMedCentralCrossRefPubMed

go back to reference Desikan RS, McEvoy LK, Thompson WK, Holland D, Roddey JC, Blennow K, Aisen PS, Brewer JB, Hyman BT, Dale AM: Alzheimer’s Disease Neuroimaging Initiative. Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann Neurol. 2011, 70: 657-61. 10.1002/ana.22509.PubMedCentralCrossRefPubMed Desikan RS, McEvoy LK, Thompson WK, Holland D, Roddey JC, Blennow K, Aisen PS, Brewer JB, Hyman BT, Dale AM: Alzheimer’s Disease Neuroimaging Initiative. Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann Neurol. 2011, 70: 657-61. 10.1002/ana.22509.PubMedCentralCrossRefPubMed

go back to reference Desikan RS, McEvoy LK, Holland D, Thompson WK, Brewer JB, Aisen PS, Andreassen OA, Hyman BT, Sperling RA, Dale AM: For the Alzheimer’s Disease Neuroimaging Initiative. Apolipoprotein E {varepsilon}4 Does Not Modulate Amyloid-β-Associated Neurodegeneration in Preclinical Alzheimer Disease. AJNR Am J Neuroradiol. 2013, 34: 505-10. 10.3174/ajnr.A3267.PubMedCentralCrossRefPubMed Desikan RS, McEvoy LK, Holland D, Thompson WK, Brewer JB, Aisen PS, Andreassen OA, Hyman BT, Sperling RA, Dale AM: For the Alzheimer’s Disease Neuroimaging Initiative. Apolipoprotein E {varepsilon}4 Does Not Modulate Amyloid-β-Associated Neurodegeneration in Preclinical Alzheimer Disease. AJNR Am J Neuroradiol. 2013, 34: 505-10. 10.3174/ajnr.A3267.PubMedCentralCrossRefPubMed

go back to reference Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM: Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002, 33: 341-55. 10.1016/S0896-6273(02)00569-X.CrossRefPubMed Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM: Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002, 33: 341-55. 10.1016/S0896-6273(02)00569-X.CrossRefPubMed

go back to reference Desikan RS, Ségonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, Buckner RL, Dale AM, Maguire RP, Hyman BT, Albert MS, Killiany RJ: An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006, 31: 968-80. 10.1016/j.neuroimage.2006.01.021.CrossRefPubMed Desikan RS, Ségonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, Buckner RL, Dale AM, Maguire RP, Hyman BT, Albert MS, Killiany RJ: An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006, 31: 968-80. 10.1016/j.neuroimage.2006.01.021.CrossRefPubMed

go back to reference Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82: 239-59. 10.1007/BF00308809.CrossRefPubMed Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82: 239-59. 10.1007/BF00308809.CrossRefPubMed

go back to reference Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW: The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer’s disease. Cereb Cortex. 1991, 1: 103-16. 10.1093/cercor/1.1.103.CrossRefPubMed Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW: The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer’s disease. Cereb Cortex. 1991, 1: 103-16. 10.1093/cercor/1.1.103.CrossRefPubMed

go back to reference Holland D, Dale AM: Nonlinear registration of longitudinal images and measurement of change in regions of interest. Med Image Anal. 2011, 15: 489-97. 10.1016/j.media.2011.02.005.PubMedCentralCrossRefPubMed Holland D, Dale AM: Nonlinear registration of longitudinal images and measurement of change in regions of interest. Med Image Anal. 2011, 15: 489-97. 10.1016/j.media.2011.02.005.PubMedCentralCrossRefPubMed